Could drug timing beat liver cancer? new study seeks answers
NCT ID NCT07285850
First seen Jan 04, 2026 · Last updated May 02, 2026 · Updated 13 times
Summary
This study tests a new way of giving two cancer drugs (bevacizumab and atezolizumab) to people with advanced liver cancer who also have fatty liver disease. Instead of giving both drugs together, researchers want to see if giving them one after the other works better. The study will enroll 20 adults and measure how well the cancer shrinks and how long people live.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Eastern Hepatobiliary Surgery Hospital
RECRUITINGShanghai, Shanghai Municipality, 201805, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.